Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Feray, C.    Bismuth, H.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Incidence of Hepatitis C in Patients Receiving Different Preparations of Hepatitis B Immunoglobulins after Liver Transplantation

Cyrille Feray, MD, PhD; Michele Gigou, MD; Didier Samuel, MD, PhD; Beatrice Ducot, MD; Pascale Maisonneuve, MD; Michel Reynes, MD; Alain Bismuth, MD; and Henri Bismuth, MD

15 May 1998 | Volume 128 Issue 10 | Pages 810-816

Background: Recurrence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection after liver transplantation is a clinical problem. Polyclonal immunoglobulins against hepatitis B surface antigen (HBIGs) prevent the recurrence of HBV infection, but no effective prophylaxis is available for HCV infection. Before screening of blood donors was introduced in France, HBIGs may have contained antibody to HCV (anti-HCV).

Objective: To determine the influence of HBIG on the occurrence of hepatitis C after liver transplantation before and after 1990.

Design: Retrospective cohort study.

Setting: Liver transplantation unit of a university hospital.

Patients: 428 consecutive patients who had liver transplantation because of cirrhosis between 1984 and 1994.

Measurements: Detection of serum HCV RNA before and 1 year after transplantation and findings on liver graft biopsy.

Results: Among the 218 patients who had HCV infection before transplantation, the incidence of HCV viremia after transplantation was lower in those receiving HBIG than in those not receiving HBIG (25 of 46 patients [54%] compared with 162 of 172 patients [94%]; P < 0.001). In patients receiving HBIG, the incidence of HCV viremia after transplantation was lower among those who had transplantation before March 1990 than among those who had transplantation after this date (15 of 33 patients [45%] compared with 10 of 13 patients [77%]; P = 0.05). Among the 210 patients without HCV infection before transplantation, acquired infection was significantly less frequent in those receiving HBIG than in those not receiving HBIG (18 of 68 patients [26%] compared with 40 of 86 patients [47%]; P < 0.001). Passively transmitted anti-HCV was transiently detected in patients receiving HBIG before March 1990. Multivariate analysis in patients with HCV infection before transplantation showed that the absence of HBIG and transplantation after March 1990 were independent significant risk factors for chronic hepatitis C after transplantation.

Conclusions: Polyclonal immunoglobulins that are treated for viral decontamination and contain anti-HCV could prevent HCV infection.

Author and Article Information

From Centre Hepato-Biliare, Laboratoire d'Anatomo-Pathologie et Transfusion Sanguine, Hopital Paul Brousse, and Universite Paris-Sud, Villcjuif, France; Centre de Transfusion Sanguine, Le Chesnay, France; and CHU Bicetre, le Kremlin-Bicetre, France.
Acknowledgments: The authors thank David Young for editorial support and Produits Roche for providing the Amplicor assays.
Grant Support: By the Direction de la Recherche Clinique Assistance Publique-Hopitaux de Paris (CRC 950175), Association pour la Recherche sur le Cancer (RO 2038), and Institut National de la Sante et de la Recherche Medicale (CRI 9804).
Requests for Reprints: Cyrille Feray, MD, Hopital Paul Brousse, 14 avenue Paul Vaillant-Couturier, 94800 Villejuif, France.
Current Author Addresses: Drs. Feray, Gigou, Samuel, Reynes, A. Bismuth, and H. Bismuth: Hopital Paul Brousse, 14 avenue Paul Vaillant-Couturier, 94800 Villejuif, France.

This article has been cited by other articles:

				J.-C. Meunier, R. S. Russell, V. Goossens, S. Priem, H. Walter, E. Depla, A. Union, K. N. Faulk, J. Bukh, S. U. Emerson, et al. Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus J. Virol., January 15, 2008; 82(2): 966 - 973. [Abstract] [Full Text] [PDF]

				D. X. Johansson, C. Voisset, A. W. Tarr, M. Aung, J. K. Ball, J. Dubuisson, and M. A. A. Persson Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus PNAS, October 9, 2007; 104(41): 16269 - 16274. [Abstract] [Full Text] [PDF]

				D. Lavillette, Y. Morice, G. Germanidis, P. Donot, A. Soulier, E. Pagkalos, G. Sakellariou, L. Intrator, B. Bartosch, J.-M. Pawlotsky, et al. Human Serum Facilitates Hepatitis C Virus Infection, and Neutralizing Responses Inversely Correlate with Viral Replication Kinetics at the Acute Phase of Hepatitis C Virus Infection J. Virol., May 15, 2005; 79(10): 6023 - 6034. [Abstract] [Full Text] [PDF]

				D. Steinmann, H. Barth, B. Gissler, P. Schurmann, M. I. Adah, J. T. Gerlach, G. R. Pape, E. Depla, D. Jacobs, G. Maertens, et al. Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C J. Virol., September 1, 2004; 78(17): 9030 - 9040. [Abstract] [Full Text] [PDF]

				M.-y. W. Yu, B. Bartosch, P. Zhang, Z.-p. Guo, P. M. Renzi, L.-m. Shen, C. Granier, S. M. Feinstone, F.-L. Cosset, and R. H. Purcell Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma PNAS, May 18, 2004; 101(20): 7705 - 7710. [Abstract] [Full Text] [PDF]

				S. Bichr, R. Rende-Fournier, G. Vona, A.-M. Yamamoto, E. Depla, G. Maertens, and C. Brechot Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model J. Gen. Virol., June 1, 2002; 83(7): 1673 - 1678. [Abstract] [Full Text] [PDF]

				K. G. Hadlock, R. E. Lanford, S. Perkins, J. Rowe, Q. Yang, S. Levy, P. Pileri, S. Abrignani, and S. K. H. Foung Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational Epitopes J. Virol., November 15, 2000; 74(22): 10407 - 10416. [Abstract] [Full Text]

				M. A. Keller and E. R. Stiehm Passive Immunity in Prevention and Treatment of Infectious Diseases Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614. [Abstract] [Full Text] [PDF]

				T. Allander, K. Drakenberg, A. Beyene, D. Rosa, S. Abrignani, M. Houghton, A. Widell, L. Grillner, and M. A. A. Persson Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81 J. Gen. Virol., October 1, 2000; 81(10): 2451 - 2459. [Abstract] [Full Text]

				J. M. Heile, Y.-L. Fong, D. Rosa, K. Berger, G. Saletti, S. Campagnoli, G. Bensi, S. Capo, S. Coates, K. Crawford, et al. Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates J. Virol., August 1, 2000; 74(15): 6885 - 6892. [Abstract] [Full Text]

				E. Lawlor, G. Columb, P. A.L. Bonis, E. Kenny-Walsh, M. Crowley, and F. Shanahan Clinical Outcomes after Hepatitis C Infection from Contaminated Anti-D Immune Globulin N. Engl. J. Med., September 2, 1999; 341(10): 762 - 763. [Full Text]

				M BERENGUER and T L WRIGHT Hepatitis C and liver transplantation Gut, August 1, 1999; 45(2): 159 - 163. [Full Text] [PDF]

				Could Postexposure Prophylaxis Prevent Hepatitis C? Journal Watch (General), May 19, 1998; 1998(519): 3 - 3. [Full Text]